Fingolimod Capsule
Product Images NDC 43598-285

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Fingolimod (NDC 43598-285). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Fingolimod Capsules 0.5 mg oral capsules package label from Dr. Reddy's Laboratories Inc. The label shows the product name, strength, quantity of 7 capsules (1 x 7 unit-dose), NDC 43598-285-70, and pharmacist dispensing instructions. The label includes storage information, distributor details, and a visual of an orange capsule with "FGU 0.5 mg" imprint.*

FDA Label Image

Carton2 (Carton2)

Fingolimod Capsules 0.5 mg unit-dose package label for oral use, distributed by Dr. Reddy's Laboratories Inc. The label indicates 30 capsules (3 x 10 unit-dose) and includes warnings that the package is not child-resistant and to keep drugs out of reach of children. The label also provides storage instructions and a barcode, with the product made in India.*

FDA Label Image

Container (Container)

Fingolimod Capsules 0.5 mg oral capsules packaging label from Dr. Reddy's Laboratories Inc. The label indicates 30 capsules per package, with instructions for pharmacists to dispense an enclosed Medication Guide. The label features a partial image of a yellow and white capsule marked with 'FGM' and '0.5 mg'. It includes standard storage instructions and a barcode along with the NDC 43598-285-30.*

FDA Label Image

Figure1 (Figure1)

A line graph showing the percentage of patients with three-month confirmed progression over time (days) comparing Fingolimod 0.5 mg and placebo. The graph uses a solid red line for Fingolimod and a dashed black line for placebo, with percentages reaching approximately 18% and 24% respectively by the end of the observation period around 720 days.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Fingolimod, showing its molecular arrangement including a phenyl ring, hydroxy groups, an amine group, and a chlorides ion indicated by Cl⁻.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.